Cannabis Use Clinical Trial
Official title:
Examining a Community Based Intervention for Cannabis Smoking Cessation in Norway - an Observational Study
NCT number | NCT04989205 |
Other study ID # | 005004 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | June 2, 2013 |
Est. completion date | January 31, 2017 |
Verified date | July 2021 |
Source | Sorlandet Hospital HF |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The study examined a community based cannabis cessation program in Norway (CCP). The CCP uses a combination of cognitive therapy and psychoeducation and covers the normal withdrawal period for cannabis smoking cessation (up to 8 weeks), comprising ~15 individual sessions. From 2005 onwards, the CCP was implemented as a low-threshold community-based program in several Norwegian municipalities, e.g., Kristiansand, Fredrikstad and Oslo. The study had an observational one-group pre- / post test design. Outcomes was changes in cannabis use, mental distress, well-being, social network and sense of coherence (SoC) measured post-intervention (T2) and at a 3 months follow-up (T3).
Status | Completed |
Enrollment | 102 |
Est. completion date | January 31, 2017 |
Est. primary completion date | January 31, 2017 |
Accepts healthy volunteers | |
Gender | All |
Age group | 16 Years and older |
Eligibility | Inclusion Criteria: - Severity of Dependence Scale (SDS) score =4 Exclusion Criteria: - polydrug use where cannabis was not the predominating substance of use - psychiatric comorbidity that was perceived as too severe to handle at the community-based centers |
Country | Name | City | State |
---|---|---|---|
Norway | Social Services, Fredrikstad Municipality | Fredrikstad | |
Norway | Kristiansand Municipality, Cannabis Cessation Program | Kristiansand | |
Norway | City Centre Outreach Service, Agency for Social and Welfare Services | Oslo |
Lead Sponsor | Collaborator |
---|---|
Sorlandet Hospital HF | City of Oslo, Municipality of Kristiansand, Norway Centre for Addiction Research |
Norway,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cannabis use | Days with cannabis use last 30 days | Changes from baseline to post-treatment and follow-up, on average 5 months | |
Secondary | Mental distress | The Hopkins Symptom Checklist (HSCL) 25-item version was used to measure mental distress. Each of the 25 items was scored on a 4-point scale (1-4). An average score was computed, indicating a global severity index of mental distress (GSI), where higher scores indicated greater distress. Clinical cut-off = 1.75 | Changes from baseline to post-treatment and follow-up, on average 5 months | |
Secondary | Well-being | The Outcome Rating Scale (ORS) was used to assess well-being. The scale has four visual analogue items on personal, interpersonal, social, and general well-being, and each item are scored from 0 = bad up to 10 = good. The items are then summed (range 0-40) and a score <25 indicated scores expected in a clinical population. | Changes from baseline to post-treatment and follow-up, on average 5 months | |
Secondary | Social network | Number of current friends with and without problematic substance use | Changes from baseline to post-treatment and follow-up, on average 5 months | |
Secondary | Sense of Coherence (SoC) | The Sense of Coherence questionnaire, 29 item version, measures the degree to which the subject feels that he or she has a sense of control over their own lives (manageability - 10 items), that life has meaning (8 items) and that their social life is understandable (comprehensibility - 11 items). Responses to items are scored on a seven-point semantic differential scale. Scores are summed (ranges from 29 - 203) and higher scores indicated a stronger SoC | Changes from baseline to post-treatment and follow-up, on average 5 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03253926 -
Effect of Lorcaserin on Cannabis Withdrawal and Self-administration
|
Phase 1/Phase 2 | |
Completed |
NCT04060602 -
Personalized Feedback Intervention to Reduce Risky Cannabis Use.
|
N/A | |
Completed |
NCT01212081 -
Assessment of Cannabis Craving in Schizophrenia Using Virtual Reality
|
||
Recruiting |
NCT04988490 -
Quantification of Cannabinoids and Comparison to Post-Surgical Pain Medication Requirements and Surgical Outcomes
|
||
Recruiting |
NCT05188404 -
Aging and Marijuana: Benefits, Effects, and Risks
|
||
Completed |
NCT03662737 -
VRT as a Biomarker of Cerebellar Dysfunction in Chronic Cannabis Use
|
||
Not yet recruiting |
NCT05999383 -
Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration
|
Phase 2 | |
Terminated |
NCT04436055 -
Intergenerational Effects of Paternal Periconceptional Cannabis and Other Drug Use (EPIC)
|
||
Active, not recruiting |
NCT04374773 -
Effects of Pregnancy-associated Hormones on THC Metabolism in Women
|
Phase 4 | |
Completed |
NCT04316741 -
Brief Intervention Combined With Health Coaching Via Social Media for Cannabis Use
|
N/A | |
Recruiting |
NCT05396638 -
Characterization of Endocannabinoid and Endogenous Opioid Levels in Adolescents With Cannabis Use Disorder
|
N/A | |
Recruiting |
NCT05309226 -
Cannabis Use in Pregnancy and Downstream Effects on Maternal and Infant Health
|
||
Recruiting |
NCT03859089 -
Cannabis for Opioid Substitution Trial
|
||
Recruiting |
NCT05849636 -
Alerta Cannabis: Evaluation of Web-based Tailored Intervention
|
N/A | |
Enrolling by invitation |
NCT05521321 -
Feasibility and Acceptability of the Cannabis Awareness and Prevention Toolkit
|
N/A | |
Recruiting |
NCT05119244 -
Environment and Lung Cancer
|
N/A | |
Recruiting |
NCT04841655 -
Tobacco Cessation Among Smokers Under Alcohol and/or Cannabis Treatment
|
||
Terminated |
NCT04100590 -
Eye Tracking as a Biomarker of Cannabis Effects
|
Phase 2 | |
Completed |
NCT05167097 -
Mindsets and the Effectiveness of a Brief Intervention - Replication
|
N/A | |
Recruiting |
NCT04114903 -
Exploring the Anti-inflammatory Properties of Cannabis and Their Relevance to Insulin Sensitivity
|